A comparative global phosphoproteomics analysis of obinutuzumab (GA101) versus rituximab (RTX) against RTX sensitive and resistant Burkitt lymphoma (BL) demonstrates differential phosphorylation of signaling pathway proteins after treatment.
about
A comparative global phosphoproteomics analysis of obinutuzumab (GA101) versus rituximab (RTX) against RTX sensitive and resistant Burkitt lymphoma (BL) demonstrates differential phosphorylation of signaling pathway proteins after treatment.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年学术文章
@wuu
2017年学术文章
@zh
2017年学术文章
@zh-cn
2017年学术文章
@zh-hans
2017年学术文章
@zh-my
2017年学术文章
@zh-sg
2017年學術文章
@yue
2017年學術文章
@zh-hant
name
A comparative global phosphopr ...... hway proteins after treatment.
@en
A comparative global phosphoproteomics analysis of obinutuzumab
@nl
type
label
A comparative global phosphopr ...... hway proteins after treatment.
@en
A comparative global phosphoproteomics analysis of obinutuzumab
@nl
prefLabel
A comparative global phosphopr ...... hway proteins after treatment.
@en
A comparative global phosphoproteomics analysis of obinutuzumab
@nl
P2093
P2860
P356
P1433
P1476
A comparative global phosphopr ...... thway proteins after treatment
@en
P2093
Aradhana Awasthi
Carmella van de Ven
Christian Klein
Damian Fermin
Delphine C M Rolland
Janet Ayello
Kevin Conlon
Matthew J Barth
Mitchell S Cairo
Venkatesha Basrur
P2860
P304
113895-113909
P356
10.18632/ONCOTARGET.23040
P407
P577
2017-12-09T00:00:00Z